The National Cancer Institute (NCI) is offering this grant to support collaborative research addressing long-term adverse effects of cancer therapies. This grant is for projects focusing on persistent, chronic, or delayed post-treatment sequelae. It encourages basic, translational, and clinical research to identify the mechanisms underlying these adverse outcomes, facilitate their clinical characterization, and develop interventional strategies. Projects should prioritize mechanistic studies with clear translational endpoints and incorporate longitudinal clinical phenotyping. The aim is to identify and validate robust clinical endpoints like biomarkers, imaging, or patient-reported outcomes. This will inform future clinical trials designed to evaluate interventions that prevent or minimize the development of these significant long-term sequelae from cancer treatments.
Opportunity ID: 335885
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-21-329 |
| Funding Opportunity Title: | Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.393 — Cancer Cause and Prevention Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Sep 22, 2021 |
| Last Updated Date: | Sep 22, 2021 |
| Original Closing Date for Applications: | Nov 05, 2024 |
| Current Closing Date for Applications: | Nov 05, 2024 |
| Archive Date: | Dec 11, 2024 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | For profit organizations other than small businesses Public and State controlled institutions of higher education Special district governments Independent school districts Native American tribal organizations (other than Federally recognized tribal governments) Small businesses City or township governments Private institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) State governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education County governments Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-21-329.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 335885 Full Announcement-PAR-21-329 -> PAR-21-329-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-F | Use for due dates on or before January 24, 2022 | PKG00269057 | Jan 05, 2022 | Jan 24, 2022 | View | |
| FORMS-G | Use for due dates on or before January 24, 2023 | PKG00269815 | Jan 05, 2022 | Jan 24, 2023 | View | |
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00277778 | Nov 01, 2022 | Nov 05, 2024 | View |
Package 1
Mandatory forms
335885 RR_SF424_2_0-2.0.pdf
335885 PHS398_CoverPageSupplement_5_0-5.0.pdf
335885 RR_OtherProjectInfo_1_4-1.4.pdf
335885 PerformanceSite_2_0-2.0.pdf
335885 RR_KeyPersonExpanded_2_0-2.0.pdf
335885 PHS398_ResearchPlan_4_0-4.0.pdf
335885 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
335885 RR_Budget_1_4-1.4.pdf
335885 RR_SubawardBudget30_1_4-1.4.pdf
335885 PHS398_ModularBudget_1_2-1.2.pdf
335885 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
335885 RR_SF424_5_0-5.0.pdf
335885 PHS398_CoverPageSupplement_5_0-5.0.pdf
335885 RR_OtherProjectInfo_1_4-1.4.pdf
335885 PerformanceSite_4_0-4.0.pdf
335885 RR_KeyPersonExpanded_4_0-4.0.pdf
335885 PHS398_ResearchPlan_4_0-4.0.pdf
335885 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
335885 RR_Budget_3_0-3.0.pdf
335885 RR_SubawardBudget30_3_0-3.0.pdf
335885 PHS398_ModularBudget_1_2-1.2.pdf
335885 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 3
Mandatory forms
335885 RR_SF424_5_0-5.0.pdf
335885 PHS398_CoverPageSupplement_5_0-5.0.pdf
335885 RR_OtherProjectInfo_1_4-1.4.pdf
335885 PerformanceSite_4_0-4.0.pdf
335885 RR_KeyPersonExpanded_4_0-4.0.pdf
335885 PHS398_ResearchPlan_5_0-5.0.pdf
335885 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
335885 RR_Budget_3_0-3.0.pdf
335885 RR_SubawardBudget30_3_0-3.0.pdf
335885 PHS398_ModularBudget_1_2-1.2.pdf
335885 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
